MYCOF News and Press, New Age Brands From 01/25/22

Researchers at the University of Virginia are conducting new research that will assist in identifying and helping individuals who are struggling with addiction, through the institution’s Center for Leading Edge Addiction Research (“CLEAR”), which develops addiction t...

Mydecine plans to launch a program to provide products and services to healthcare professionals, clinics, and hospitals in Canada looking to treat patients through psychedelic-assisted psychotherapy The products and services, which will be available for purchase as a package, include cG...

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) announced that it would be launching a special access psychedelic-assisted psychotherapy program , called the Special Access Support and Supply Program. The program will be available to patients who require alternative treatment mod...

DENVER, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, tod...

A new study has found that the leaders of Wari may have laced their beer with hallucinogens to keep their political control for centuries. The drugs are said to have been extracted from plant seeds. The Wari are a South American civilization that ruled the highlands of what is now known as...

A new study conducted by researchers at the University of Arizona Health Sciences has found that sleep deprivation can cause a significant increase in serotonin 2A levels in a matter of hours in animal models.Serotonin 2A, or the 5-HT2A receptor, plays a crucial role in cognition, percepti...

Canada held its first legal psilocybin therapy group session recently. Psilocybin is an active hallucinogenic compound found in magic mushrooms. Various studies conducted by major research institutions have found that psilocybin possesses therapeutic benefits. For instance, studies by Joh...

Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and development He noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to o...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into a letter of intent (“LOI”) with The Newly Institute Inc. (...

Under Mydecine's recently announced Special Access Support and Supply Program, the company will supply cGMP Psilocybin and MDMA to The Newly. The companies will partner to co-develop protocols, therapy manuals, and training needed to treat patients who need specific care. Calgary, Alberta--(N...